Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28,495,649
-
Total 13F shares
-
8,316,794
-
Share change
-
-400,263
-
Total reported value
-
$11,476,217
-
Price per share
-
$1.38
-
Number of holders
-
14
-
Value change
-
-$815,784
-
Number of buys
-
4
-
Number of sells
-
10
Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q4 2018
As of 31 Dec 2018,
Oncocyte Corporation - Common Shares, No Par Value (OCX) was held by
14 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,316,794 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, Vanguard Group Inc, BRIDGEWAY CAPITAL MANAGEMENT INC, BlackRock Inc., Destination Wealth Management, MORGAN STANLEY, COMMONWEALTH EQUITY SERVICES, LLC, GEODE CAPITAL MANAGEMENT, LLC, Williams Jones & Associates LLC, and NORTHERN TRUST CORP.
This page lists
14
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.